clomipramine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
substances of the imipramine group	701	303-49-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clomipramine chlorimipramine clomipramine hydrochloride clomipramine HCl	A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. Molecular weight: 314.86 Formula: C19H23ClN2 CLOGP: 5.92 LIPINSKI: 1 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.34 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clomipramine
chlorimipramine
clomipramine hydrochloride
clomipramine HCl

A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.

Molecular weight: 314.86
Formula: C19H23ClN2
CLOGP: 5.92
LIPINSKI: 1
HAC: 2
HDO: 0
TPSA: 6.48
ALOGS: -4.34
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.10	g	O
0.10	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	13.24 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	51 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	13 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.03 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	26 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 29, 1989	FDA	MALLINCKRODT LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	214.31	16.20	137	10745	59518	56221667
Intentional overdose	190.73	16.20	134	10748	67983	56213202
Serotonin syndrome	173.44	16.20	90	10792	26400	56254785
Drug interaction	149.74	16.20	193	10689	209562	56071623
Suicide attempt	130.65	16.20	100	10782	57736	56223449
Overdose	129.55	16.20	129	10753	105701	56175484
Bezoar	116.99	16.20	31	10851	1337	56279848
Poisoning deliberate	111.66	16.20	49	10833	9904	56271281
Toxicity to various agents	102.11	16.20	167	10715	224397	56056788
Intentional self-injury	98.66	16.20	61	10821	24931	56256254
Depressed level of consciousness	86.55	16.20	78	10804	56355	56224830
Antipsychotic drug level increased	82.87	16.20	29	10853	3213	56277972
Neuroleptic malignant syndrome	77.96	16.20	40	10842	11438	56269747
Sopor	74.88	16.20	48	10834	20874	56260311
Electrocardiogram QT prolonged	67.54	16.20	67	10815	54521	56226664
Tachycardia	65.47	16.20	91	10791	105785	56175400
Antidepressant drug level increased	58.65	16.20	13	10869	260	56280925
Altered state of consciousness	56.79	16.20	42	10840	22979	56258206
Hypertonia	55.32	16.20	23	10859	4069	56277116
International normalised ratio abnormal	55.06	16.20	21	10861	2967	56278218
Hyperthermia	50.90	16.20	27	10855	8258	56272927
Suicidal ideation	50.50	16.20	59	10823	57683	56223502
Pain	49.49	16.20	34	10848	663150	55618035
Drug abuse	49.27	16.20	63	10819	67547	56213638
Cerebellar syndrome	48.61	16.20	20	10862	3447	56277738
Agitation	48.58	16.20	57	10825	55979	56225206
Somnolence	48.20	16.20	101	10781	163312	56117873
Myoclonus	47.38	16.20	32	10850	15171	56266014
Tremor	46.91	16.20	84	10798	121005	56160180
Rheumatoid arthritis	46.20	16.20	9	10873	382595	55898590
Sinus tachycardia	44.56	16.20	36	10846	22408	56258777
Akathisia	44.31	16.20	25	10857	8627	56272558
Livedo reticularis	42.23	16.20	16	10866	2219	56278966
Confusional state	42.10	16.20	111	10771	208044	56073141
Hypotension	39.40	16.20	122	10760	250386	56030799
Polyuria	39.16	16.20	22	10860	7529	56273656
Joint swelling	39.06	16.20	5	10877	289795	55991390
Hyposmia	38.82	16.20	11	10871	610	56280575
Psychomotor hyperactivity	38.81	16.20	24	10858	9796	56271389
Ventricular dyskinesia	38.01	16.20	8	10874	124	56281061
Obsessive-compulsive disorder	37.56	16.20	17	10865	3689	56277496
Hyperchloraemia	36.96	16.20	11	10871	726	56280459
Mental disorder	36.89	16.20	33	10849	23571	56257614
Arthralgia	35.68	16.20	27	10855	501642	55779543
Alopecia	35.20	16.20	7	10875	293451	55987734
Pneumonia aspiration	33.25	16.20	36	10846	32375	56248810
Poisoning	33.00	16.20	24	10858	12789	56268396
Urinary retention	32.03	16.20	33	10849	28041	56253144
Parkinsonism	31.93	16.20	21	10861	9525	56271660
Hypotonia	31.26	16.20	20	10862	8657	56272528
Fatigue	30.70	16.20	67	10815	788485	55492700
Diarrhoea	30.36	16.20	48	10834	638459	55642726
Restlessness	29.88	16.20	31	10851	26555	56254630
Muscle rigidity	29.81	16.20	21	10861	10650	56270535
Disturbance in attention	29.70	16.20	34	10848	32506	56248679
Cor pulmonale acute	29.60	16.20	8	10874	372	56280813
Drug withdrawal syndrome neonatal	29.52	16.20	12	10870	2004	56279181
Mydriasis	29.11	16.20	21	10861	11050	56270135
Psychomotor skills impaired	28.83	16.20	12	10870	2128	56279057
Newborn persistent pulmonary hypertension	28.43	16.20	7	10875	224	56280961
Miosis	28.33	16.20	17	10865	6575	56274610
Post-anoxic myoclonus	27.49	16.20	5	10877	34	56281151
Inappropriate antidiuretic hormone secretion	27.16	16.20	22	10860	13734	56267451
Urine osmolarity increased	27.07	16.20	6	10876	120	56281065
Blood prolactin increased	26.80	16.20	13	10869	3296	56277889
Drug level increased	26.65	16.20	26	10856	20699	56260486
Otorrhoea	26.46	16.20	10	10872	1377	56279808
Hallucination, auditory	26.14	16.20	20	10862	11504	56269681
Retroplacental haematoma	25.83	16.20	6	10876	149	56281036
Shock	25.62	16.20	26	10856	21702	56259483
Psychomotor retardation	25.53	16.20	13	10869	3656	56277529
Onychophagia	25.02	16.20	5	10877	59	56281126
Circulatory collapse	24.72	16.20	25	10857	20778	56260407
Hepatocellular injury	24.69	16.20	28	10854	26486	56254699
Cyanosis	24.50	16.20	22	10860	15788	56265397
Product dose omission issue	24.29	16.20	5	10877	204748	56076437
Depression	24.03	16.20	83	10799	180034	56101151
Mania	23.97	16.20	19	10863	11501	56269684
Spasmodic dysphonia	23.67	16.20	5	10877	79	56281106
Rash	23.46	16.20	37	10845	493010	55788175
Contraindicated product administered	23.27	16.20	4	10878	186282	56094903
Electrocardiogram QRS complex prolonged	23.24	16.20	14	10868	5453	56275732
Nasopharyngitis	23.11	16.20	7	10875	220952	56060233
Apathy	23.03	16.20	16	10866	7938	56273247
Hypokalaemia	22.88	16.20	54	10828	94383	56186802
Nephrogenic diabetes insipidus	22.80	16.20	8	10874	892	56280293
Treatment failure	22.79	16.20	3	10879	170389	56110796
Lactic acidosis	22.74	16.20	31	10851	35315	56245870
Therapeutic product effect decreased	22.63	16.20	3	10879	169449	56111736
Asphyxia	22.50	16.20	14	10868	5775	56275410
Hyponatraemia	22.18	16.20	56	10826	102083	56179102
Peripheral swelling	21.88	16.20	9	10873	234717	56046468
Arthropathy	21.58	16.20	6	10876	200269	56080916
Anxiety	21.54	16.20	84	10798	193088	56088097
Paralogism	21.42	16.20	4	10878	32	56281153
Swelling	21.08	16.20	10	10872	239761	56041424
Cholestasis	21.06	16.20	26	10856	26887	56254298
Right ventricular dilatation	20.99	16.20	8	10874	1128	56280057
Hyperhidrosis	20.87	16.20	52	10830	94036	56187149
Tardive dyskinesia	20.58	16.20	15	10867	8016	56273169
Drug hypersensitivity	20.58	16.20	14	10868	275191	56005994
Foetal arrhythmia	20.37	16.20	5	10877	158	56281027
Heat stroke	20.25	16.20	7	10875	747	56280438
Dialysis	20.18	16.20	16	10866	9686	56271499
Stereotypy	19.87	16.20	6	10876	416	56280769
Infection	19.78	16.20	7	10875	200199	56080986
Drug screen false positive	19.68	16.20	7	10875	813	56280372
Respiratory depression	18.67	16.20	17	10865	12418	56268767
Hypernatraemia	18.42	16.20	13	10869	6607	56274578
Hyporesponsive to stimuli	18.34	16.20	7	10875	991	56280194
Acquired haemophilia	18.16	16.20	7	10875	1017	56280168
Rhabdomyolysis	18.07	16.20	30	10852	40628	56240557
Morbid thoughts	18.03	16.20	6	10876	570	56280615
Loss of consciousness	17.83	16.20	54	10828	109295	56171890
Toxic skin eruption	17.53	16.20	16	10866	11723	56269462
Headache	17.45	16.20	53	10829	558991	55722194
Otitis media	17.31	16.20	11	10871	4705	56276480
Hyperprolactinaemia	17.20	16.20	10	10872	3651	56277534
Abdominal discomfort	17.14	16.20	17	10865	277257	56003928
Intestinal gangrene	17.12	16.20	3	10879	16	56281169
Psychiatric symptom	17.04	16.20	11	10871	4833	56276352
Anticholinergic syndrome	16.88	16.20	8	10874	1926	56279259
Junctional ectopic tachycardia	16.73	16.20	4	10878	113	56281072

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Obsessive-compulsive disorder	299.12	20.90	90	7716	4847	31684691
Suicide attempt	271.20	20.90	147	7659	37101	31652437
Therapeutic product effect variable	260.09	20.90	66	7740	1872	31687666
Antipsychotic drug level below therapeutic	252.65	20.90	65	7741	1950	31687588
Disinhibition	238.56	20.90	66	7740	2627	31686911
Euphoric mood	219.55	20.90	71	7735	4849	31684689
Akathisia	203.70	20.90	74	7732	7179	31682359
Increased appetite	186.66	20.90	67	7739	6277	31683261
Toxicity to various agents	132.50	20.90	191	7615	181296	31508242
Intentional overdose	132.22	20.90	97	7709	41292	31648246
Serotonin syndrome	103.79	20.90	62	7744	18711	31670827
Coma	99.92	20.90	82	7724	41068	31648470
Poisoning deliberate	95.17	20.90	43	7763	7301	31682237
Neuroleptic malignant syndrome	91.40	20.90	55	7751	16814	31672724
Dyslipidaemia	81.39	20.90	37	7769	6369	31683169
Electrocardiogram QT prolonged	80.47	20.90	70	7736	37917	31651621
Therapeutic product effect incomplete	79.70	20.90	74	7732	43622	31645916
Leukaemia	76.78	20.90	31	7775	3994	31685544
Obesity	72.85	20.90	41	7765	11059	31678479
Leukopenia	69.15	20.90	78	7728	57750	31631788
Prescribed overdose	68.72	20.90	37	7769	9155	31680383
Weight increased	67.21	20.90	92	7714	82855	31606683
Sopor	63.42	20.90	38	7768	11514	31678024
Intentional self-injury	60.93	20.90	39	7767	13276	31676262
Extrapyramidal disorder	52.65	20.90	34	7772	11744	31677794
Somnolence	50.60	20.90	89	7717	99356	31590182
Agitation	46.75	20.90	62	7744	54107	31635431
Overdose	45.97	20.90	78	7728	84586	31604952
Compartment syndrome	42.24	20.90	18	7788	2653	31686885
Drug interaction	40.63	20.90	128	7678	208415	31481123
Schizoaffective disorder	39.49	20.90	14	7792	1261	31688277
Renal hypertension	38.77	20.90	9	7797	173	31689365
Loose associations	35.91	20.90	7	7799	55	31689483
Mania	35.00	20.90	24	7782	9153	31680385
Brachial plexus injury	34.05	20.90	7	7799	74	31689464
Tremor	30.86	20.90	62	7744	76358	31613180
Fatigue	30.39	20.90	23	7783	335183	31354355
Rhabdomyolysis	29.86	20.90	55	7751	63526	31626012
Hypothermia	29.58	20.90	22	7784	9522	31680016
Aggression	28.10	20.90	40	7766	37251	31652287
Hypertonia neonatal	26.54	20.90	8	7798	431	31689107
Inappropriate antidiuretic hormone secretion	26.15	20.90	22	7784	11365	31678173
Coma scale abnormal	25.09	20.90	14	7792	3709	31685829
Pneumonia	24.49	20.90	28	7778	335284	31354254
Diarrhoea	24.07	20.90	31	7775	352378	31337160
Cataplexy	23.69	20.90	7	7799	352	31689186
Cough	23.05	20.90	3	7803	134811	31554727
Drug ineffective	22.99	20.90	171	7635	395402	31294136
Depressed level of consciousness	22.84	20.90	37	7769	38564	31650974
Bradykinesia	22.83	20.90	13	7793	3579	31685959
Dyspraxia	22.63	20.90	7	7799	412	31689126
Pain	22.40	20.90	9	7797	186750	31502788
Hyperthermia	22.29	20.90	19	7787	9985	31679553
Drug withdrawal syndrome	21.87	20.90	25	7781	18725	31670813
Hallucination, auditory	21.72	20.90	19	7787	10341	31679197
Feelings of worthlessness	20.91	20.90	6	7800	272	31689266

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	309.24	16.87	211	15082	91633	70821518
Intentional overdose	270.91	16.87	200	15093	98235	70814916
Suicide attempt	263.62	16.87	181	15112	79329	70833822
Serotonin syndrome	258.12	16.87	142	15151	41972	70871179
Poisoning deliberate	192.13	16.87	87	15206	16973	70896178
Neuroleptic malignant syndrome	174.05	16.87	93	15200	25914	70887237
Drug interaction	159.13	16.87	290	15003	381151	70532000
Overdose	150.46	16.87	184	15109	169561	70743590
Toxicity to various agents	149.91	16.87	283	15010	381889	70531262
Sopor	134.83	16.87	84	15209	31183	70881968
Bezoar	127.32	16.87	38	15255	2268	70910883
Electrocardiogram QT prolonged	124.06	16.87	119	15174	83398	70829753
Intentional self-injury	104.61	16.87	72	15221	31578	70881573
Obsessive-compulsive disorder	102.90	16.87	40	15253	5330	70907821
Somnolence	90.97	16.87	165	15128	215441	70697710
Akathisia	85.15	16.87	45	15248	12248	70900903
Hyperthermia	74.92	16.87	46	15247	16625	70896526
Depressed level of consciousness	74.46	16.87	93	15200	87338	70825813
Agitation	72.71	16.87	95	15198	93280	70819871
Altered state of consciousness	65.07	16.87	60	15233	39962	70873189
Suicidal ideation	62.42	16.87	76	15217	69520	70843631
Tremor	61.67	16.87	116	15177	155508	70757643
Tachycardia	60.14	16.87	116	15177	158430	70754721
Pain	59.20	16.87	31	15262	628785	70284366
Mania	58.94	16.87	40	15253	17134	70896017
Antidepressant drug level increased	57.24	16.87	14	15279	389	70912762
Antipsychotic drug level increased	55.76	16.87	26	15267	5414	70907737
Psychomotor hyperactivity	53.09	16.87	36	15257	15397	70897754
Confusional state	52.22	16.87	157	15136	284241	70628910
Rhabdomyolysis	51.86	16.87	82	15211	95678	70817473
Parkinsonism	48.59	16.87	34	15259	15291	70897860
Diarrhoea	45.14	16.87	62	15231	783279	70129872
Antipsychotic drug level below therapeutic	44.86	16.87	14	15279	971	70912180
Fatigue	44.80	16.87	68	15225	824251	70088900
Shock	44.38	16.87	49	15244	40376	70872775
Arthralgia	44.19	16.87	27	15266	503363	70409788
Extrapyramidal disorder	43.58	16.87	36	15257	20714	70892437
Inappropriate antidiuretic hormone secretion	41.97	16.87	37	15256	23239	70889912
Myoclonus	41.84	16.87	39	15254	26316	70886835
Cerebellar syndrome	41.55	16.87	21	15272	5210	70907941
International normalised ratio abnormal	41.49	16.87	21	15272	5226	70907925
Hallucination, auditory	41.02	16.87	33	15260	18295	70894856
Pneumonia aspiration	40.35	16.87	58	15235	62231	70850920
Drug abuse	38.82	16.87	93	15200	147163	70765988
Renal hypertension	38.68	16.87	9	15284	201	70912950
Joint swelling	37.72	16.87	5	15288	253206	70659945
Psychomotor retardation	37.37	16.87	20	15273	5578	70907573
Therapeutic product effect variable	37.29	16.87	14	15279	1696	70911455
Sinus tachycardia	37.04	16.87	41	15252	33872	70879279
Peripheral swelling	36.90	16.87	4	15289	236559	70676592
Nasopharyngitis	36.66	16.87	3	15290	222203	70690948
Disinhibition	36.64	16.87	15	15278	2286	70910865
Loose associations	36.51	16.87	7	15286	58	70913093
Muscle rigidity	36.36	16.87	31	15262	18619	70894532
Polyuria	36.24	16.87	27	15266	13379	70899772
Euphoric mood	36.12	16.87	21	15272	6868	70906283
Compartment syndrome	35.60	16.87	18	15275	4468	70908683
Rheumatoid arthritis	34.62	16.87	10	15283	291795	70621356
Hypertonia	34.58	16.87	20	15273	6478	70906673
Apathy	34.48	16.87	25	15268	11883	70901268
Hepatocellular injury	34.47	16.87	46	15247	46045	70867106
Hyposmia	33.11	16.87	10	15283	621	70912530
Livedo reticularis	32.39	16.87	16	15277	3782	70909369
Hyperchloraemia	32.35	16.87	11	15282	1001	70912150
Mental disorder	32.33	16.87	35	15258	28205	70884946
Brachial plexus injury	32.17	16.87	7	15286	114	70913037
Mydriasis	31.80	16.87	27	15266	16126	70897025
Bronchial hyperreactivity	31.48	16.87	14	15279	2612	70910539
Hyperhidrosis	31.39	16.87	80	15213	131506	70781645
Urinary retention	31.26	16.87	47	15246	52473	70860678
Bradykinesia	29.44	16.87	19	15274	7483	70905668
Electrocardiogram QRS complex prolonged	29.34	16.87	21	15272	9785	70903366
Infusion related reaction	29.18	16.87	4	15289	197530	70715621
Circulatory collapse	29.00	16.87	37	15256	35437	70877714
Rash	28.75	16.87	41	15252	510521	70402630
Miosis	28.64	16.87	24	15269	14077	70899074
Pressure of speech	28.25	16.87	10	15283	1025	70912126
Schizoaffective disorder	28.22	16.87	12	15281	2011	70911140
Ventricular dyskinesia	28.17	16.87	8	15285	400	70912751
Coma scale abnormal	28.07	16.87	19	15274	8097	70905054
Restlessness	26.94	16.87	39	15254	42089	70871062
Seizure	26.92	16.87	92	15201	177870	70735281
Depression	26.79	16.87	99	15194	198875	70714276
Loss of consciousness	26.69	16.87	84	15209	155632	70757519
Retroplacental haematoma	26.61	16.87	6	15287	116	70913035
Prescribed overdose	26.52	16.87	31	15262	27150	70886001
Abdominal pain	26.47	16.87	21	15272	342106	70571045
Disturbance in attention	26.40	16.87	39	15254	42855	70870296
Intentional product misuse	26.27	16.87	55	15238	79540	70833611
Febrile neutropenia	26.14	16.87	6	15287	204312	70708839
Asphyxia	26.12	16.87	20	15273	10322	70902829
Anxiety	25.89	16.87	105	15188	220225	70692926
Poisoning	25.83	16.87	28	15265	22594	70890557
Nausea	25.66	16.87	96	15197	851992	70061159
Speech disorder	25.57	16.87	42	15251	50538	70862613
Breast disorder	25.34	16.87	11	15282	1938	70911213
Drug level increased	25.15	16.87	35	15258	36434	70876717
Hypotension	25.11	16.87	161	15132	404220	70508931
Post-anoxic myoclonus	24.80	16.87	5	15288	55	70913096
Product dose omission issue	24.79	16.87	8	15285	217460	70695691
Hypothermia	24.41	16.87	26	15267	20568	70892583
Generalised tonic-clonic seizure	24.39	16.87	37	15256	41624	70871527
Cor pulmonale acute	24.37	16.87	8	15285	653	70912498
Otorrhoea	23.91	16.87	10	15283	1608	70911543
Blood prolactin increased	23.91	16.87	13	15280	3741	70909410
Withdrawal syndrome	23.63	16.87	28	15265	24876	70888275
Pain in extremity	23.12	16.87	22	15271	328060	70585091
Cough	22.72	16.87	22	15271	325355	70587796
Psychomotor skills impaired	22.31	16.87	13	15280	4271	70908880
Pneumonia	22.23	16.87	61	15232	596171	70316980
Onychophagia	22.06	16.87	5	15288	99	70913052
Obesity	22.01	16.87	28	15265	26743	70886408
Psychiatric symptom	21.67	16.87	15	15278	6629	70906522
Abulia	21.65	16.87	8	15285	927	70912224
Urine osmolarity increased	21.61	16.87	6	15287	276	70912875
Aggression	21.54	16.87	38	15255	48408	70864743
Dyspraxia	21.53	16.87	6	15287	280	70912871
Alopecia	21.42	16.87	8	15285	198482	70714669
Paralogism	20.99	16.87	4	15289	32	70913119
Cataplexy	20.98	16.87	8	15285	1011	70912140
Heat stroke	20.90	16.87	9	15284	1554	70911597
Therapeutic product effect decreased	20.87	16.87	3	15290	143015	70770136
Pleurothotonus	20.27	16.87	10	15283	2356	70910795
Clonus	20.09	16.87	14	15279	6254	70906897
Arthropathy	20.02	16.87	4	15289	150053	70763098
Hypokalaemia	19.98	16.87	68	15225	131120	70782031
Morbid thoughts	19.48	16.87	7	15286	749	70912402
Nephrogenic diabetes insipidus	18.94	16.87	9	15284	1954	70911197
Hypernatraemia	18.57	16.87	18	15275	12743	70900408
Obsessive-compulsive symptom	18.57	16.87	5	15288	205	70912946
Dyslipidaemia	18.43	16.87	16	15277	9844	70903307
Product use in unapproved indication	18.43	16.87	91	15202	207387	70705764
Headache	18.35	16.87	64	15229	580341	70332810
Social anxiety disorder	18.28	16.87	6	15287	489	70912662
Major depression	18.26	16.87	15	15278	8559	70904592
Spasmodic dysphonia	18.25	16.87	5	15288	219	70912932
Feelings of worthlessness	18.21	16.87	6	15287	495	70912656
Anticholinergic syndrome	18.10	16.87	10	15283	2970	70910181
Stomatitis	18.06	16.87	3	15290	128508	70784643
Hyperreflexia	17.94	16.87	14	15279	7428	70905723
Disorientation	17.92	16.87	39	15254	57884	70855267
Hypersensitivity	17.90	16.87	14	15279	229798	70683353
Sepsis	17.69	16.87	16	15277	244529	70668622
Completed suicide	17.66	16.87	96	15197	227039	70686112
Blood creatine phosphokinase increased	17.55	16.87	40	15253	61223	70851928
Increased appetite	17.41	16.87	16	15277	10597	70902554
Drug screen false positive	17.36	16.87	7	15286	1026	70912125
Stupor	17.35	16.87	13	15280	6496	70906655
Hepatic cytolysis	17.26	16.87	21	15272	19171	70893980
Right ventricular dilatation	17.19	16.87	8	15285	1657	70911494
Hypovolaemic shock	17.13	16.87	16	15277	10821	70902330
Contraindicated product administered	17.12	16.87	4	15289	134608	70778543
Irritability	17.02	16.87	30	15263	38195	70874956
Hyponatraemia	17.00	16.87	74	15219	160013	70753138
Death	16.96	16.87	55	15238	510006	70403145

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N06AA04	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Non-selective monoamine reuptake inhibitors
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:48278	serotonergic drugs
CHEBI has role	CHEBI:48279	serotonin antagonists
CHEBI has role	CHEBI:149553	anticoronaviral drug
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D018490	Serotonin Agents
MeSH PA	D017367	Serotonin Uptake Inhibitors
FDA EPC	N0000175752	Tricyclic Antidepressant
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:77402	EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Obsessive-compulsive disorder	indication	191736004	DOID:10933
Depressive disorder	off-label use	35489007
Cataplexy	off-label use	46263000
Anxiety	off-label use	48694002
Panic disorder	off-label use	371631005	DOID:594
Suicidal thoughts	contraindication	6471006
Alcoholism	contraindication	7200002
Glaucoma	contraindication	23986001	DOID:1686
Hyperthyroidism	contraindication	34486009	DOID:7998
Acute nephropathy	contraindication	58574008
Epilepsy	contraindication	84757009	DOID:1826
Bipolar affective disorder, current episode manic	contraindication	191618007
Disease of liver	contraindication	235856003	DOID:409
Retention of urine	contraindication	267064002
Pheochromocytoma	contraindication	302835009
Malignant hyperthermia	contraindication	405501007
Myocardial infarction in recovery phase	contraindication	418044006
Neuroblastoma	contraindication	432328008	DOID:769
Atrioventricular Conduction Defect	contraindication

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Separation anxiety	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Clomicalm Tablets	Virbac AH Inc.	1
Clomipramine Hydrochloride Tablets	Mizner Bioscience LLC	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.04	Basic
pKa2	6.19	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Kd	7.42	WOMBAT-PK	IUPHAR
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	9.70	PDSP	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.28	PDSP
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.24	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	7.45	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.82	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	7.19	PDSP
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.95	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	8.50	WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.34	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	7.41	PDSP
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.01	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.70	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.66	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.07	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	7.44	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	7.89	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.42	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.32	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.69	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		IC50	5.56	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.66	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.40	DRUG MATRIX
Glutathione S-transferase P	Enzyme	P09211	GSTP1_HUMAN				WOMBAT-PK
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.71	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	6.66	PDSP
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.95	PDSP
Trypanothione reductase	Enzyme		TYTR_TRYCR		Ki	5.19	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.14	DRUG MATRIX
Membrane-associated progesterone receptor component 1	Membrane receptor		PGRC1_RAT		Ki	5.94	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	10.40	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	7.25	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter		SC6A2_MOUSE		IC50	6.05	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_MOUSE		IC50	7.15	CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	9.70	CHEMBL
Serotonin (5-HT) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT 5HT2B_RAT 5HT6R_RAT 5HT7R_RAT 5HT5A_RAT 5HT5B_RAT 5HT3A_RAT 5HT4R_RAT 5HT3B_RAT		IC50	8.30	CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT		Ki	5.30	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2B_RAT ADA2C_RAT ADA2A_RAT		Ki	7.29	CHEMBL
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	8.08	CHEMBL
Trypanothione reductase	Enzyme		TYTR_TRYBB		IC50	5.47	CHEMBL
G protein-activated inward rectifier potassium channel 2	Ion channel		KCNJ6_MOUSE	BLOCKER	IC50	4.40	IUPHAR

External reference:

ID	Source
4019687	VUID
N0000147779	NUI
D00811	KEGG_DRUG
17321-77-6	SECONDARY_CAS_RN
2597	RXNORM
4019492	VANDF
4019687	VANDF
C0009010	UMLSCUI
CHEBI:47780	CHEBI
CXX	PDB_CHEM_ID
CHEMBL415	ChEMBL_ID
CHEMBL1200710	ChEMBL_ID
DB01242	DRUGBANK_ID
D002997	MESH_DESCRIPTOR_UI
2801	PUBCHEM_CID
2398	IUPHAR_LIGAND_ID
2238	INN_ID
NUV44L116D	UNII
373	MMSL
4476	MMSL
d00876	MMSL
003456	NDDF
004614	NDDF
372903001	SNOMEDCT_US
387027004	SNOMEDCT_US
96209002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3025	CAPSULE	25 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3050	CAPSULE	50 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-3075	CAPSULE	75 mg	ORAL	ANDA	25 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8806	CAPSULE	25 mg	ORAL	NDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8807	CAPSULE	50 mg	ORAL	NDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0406-8808	CAPSULE	75 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9906	CAPSULE	25 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9907	CAPSULE	50 mg	ORAL	NDA	24 sections
ANAFRANIL	HUMAN PRESCRIPTION DRUG LABEL	1	0406-9908	CAPSULE	75 mg	ORAL	NDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2027	CAPSULE	25 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0781-2037	CAPSULE	50 mg	ORAL	ANDA	25 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0630	CAPSULE	25 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0631	CAPSULE	50 mg	ORAL	ANDA	24 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0632	CAPSULE	75 mg	ORAL	ANDA	24 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7038	CAPSULE	25 mg	ORAL	ANDA	26 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7039	CAPSULE	50 mg	ORAL	ANDA	26 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-698	CAPSULE	25 mg	ORAL	ANDA	27 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-699	CAPSULE	50 mg	ORAL	ANDA	27 sections
clomiPRAMINE Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	10135-700	CAPSULE	75 mg	ORAL	ANDA	27 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-683	CAPSULE	25 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-684	CAPSULE	50 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	Human Prescription Drug Label	1	16571-685	CAPSULE	75 mg	ORAL	ANDA	23 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-849	CAPSULE	25 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-850	CAPSULE	50 mg	ORAL	ANDA	21 sections
Clomipramine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	16714-851	CAPSULE	75 mg	ORAL	ANDA	21 sections
Clomipramine hydrochloride	Human Prescription Drug Label	1	27241-210	CAPSULE	25 mg	ORAL	ANDA	23 sections
Clomipramine hydrochloride	Human Prescription Drug Label	1	27241-211	CAPSULE	50 mg	ORAL	ANDA	23 sections
Clomipramine hydrochloride	Human Prescription Drug Label	1	27241-212	CAPSULE	75 mg	ORAL	ANDA	23 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-342	CAPSULE	25 mg	ORAL	ANDA	23 sections
CLOMIPRAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-343	CAPSULE	50 mg	ORAL	ANDA	23 sections